Clinical Management of EGFR-Mutated Advanced NSCLC

Compare first-line EGFR-mutated lung cancer options: amivantamab combos vs osimertinib plus chemo, weighing survival, MET amplification coverage, toxicity, and visits.

New data show subcutaneous amivantamab matches IV efficacy, cuts infusion reactions and steroid prep, and slashes clinic time and costs.

PALOMA-3: subcutaneous amivantamab matches IV levels, slashes infusion reactions and steroids, and shortens clinic time.

New subcutaneous amivantamab cuts infusion reactions and steroid burden, reduces clinic visits, and shows improved outcomes in PALOMA-3.

High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for rapid symptom relief.

High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for quicker symptom relief.